

ORASURE TECHNOLOGIES INC  
Form 8-K  
May 16, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): May 15, 2012**

**OraSure Technologies, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction

of Incorporation)

**001-16537**  
(Commission

File Number)

**36-4370966**  
(I.R.S. Employer

Identification No.)

Edgar Filing: ORASURE TECHNOLOGIES INC - Form 8-K

**220 East First Street**

**Bethlehem, Pennsylvania**  
(Address of Principal Executive Offices)

**Registrant's telephone number, including area code: 610-882-1820**

**18015-1360**  
(Zip Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

The following is a summary of the items considered by stockholders and the corresponding voting results at the OraSure Technologies, Inc. (the Company) Annual Meeting of Stockholders held on May 15, 2012:

**Item 1 Election of Class III Directors for Terms Expiring at the 2015 Annual Meeting of Stockholders.**

| Nominee            | Votes For  | Votes Withheld | Broker Non-Votes |
|--------------------|------------|----------------|------------------|
| Michael Celano     | 34,979,229 | 1,471,667      | 8,565,422        |
| Douglas A. Michels | 34,813,668 | 1,637,228      | 8,565,422        |
| Charles W. Patrick | 34,987,129 | 1,463,767      | 8,565,422        |

**Item 2 Ratification of Appointment of KPMG, LLP as the Company's Independent Registered Public Accounting Firm for 2012.**

| Votes For  | Votes Against | Abstentions |
|------------|---------------|-------------|
| 44,559,964 | 433,429       | 22,925      |

**Item 3 Non-Binding Advisory Resolution Approving Executive Compensation.**

| Votes For  | Votes Against | Abstentions | Broker Non-Votes |
|------------|---------------|-------------|------------------|
| 30,815,374 | 5,601,807     | 33,715      | 8,565,422        |

**Item 7.01 Regulation FD Disclosure.**

On May 15, 2012, the Company issued a press release announcing the results of the U.S. Food and Drug Administration's Blood Products Advisory Committee review of the Company's application for premarket approval of its OraQuick<sup>®</sup> In-Home HIV test for sale in the U.S. consumer or over-the-counter market. A copy of the press release is attached as Exhibit 99 to this Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.****(d) Exhibits**

| Exhibit Number | Description   |
|----------------|---|
| 99             | Press Release, dated May 15, 2012, announcing the results of the U.S. Food and Drug Administration's Blood Products Advisory Committee review of the Company's application for premarket approval of its OraQuick <sup>®</sup> In-Home HIV test for sale in the U.S. consumer or over-the-counter market. |

**Signatures**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ORASURE TECHNOLOGIES, INC.

Date: May 16, 2012

By: */s/ Jack E. Jerrett*  
Jack E. Jerrett  
Senior Vice President, General Counsel and Secretary

**Index to Exhibits**

**Exhibit  
No.**

**Description**

|    |  |
|----|--|
| 99 | Press Release, dated May 15, 2012, announcing the results of the U.S. Food and Drug Administration's Blood Products Advisory Committee review of the Company's application for premarket approval of its OraQuick In-Home HIV test for sale in the U.S. consumer or over-the-counter market. |
|----|--|